Abstract
FDA recently approved the marketing of the first neostigmine product for use in reversing the effects of nondepolarizing neuromuscular blocking agents (NMBAs) after surgery. Neostigmine methylsulfate injection has been available for decades, but until May 31 no company had an FDA-approved new drug
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
